Fig 3.

Reported use of 26 Gy in five fractions (26Gy5F) radiotherapy regimen among women receiving postoperative radiotherapy between July 2019 and July 2020, overall and by (a) age at diagnosis, (b) type of surgery, (c) nodal status and (d) stage. Note: for women diagnosed in England, axillary node dissection recorded within Hospital Episode Statistics or having stage 3A disease (N stage contribution defined as having N1/N2 disease) were used as a proxy for nodal involvement (N+); coded as NX otherwise. ‘Mastectomy – N0 & not T3’ = use following mastectomy for N0 small tumours (<T3) being the cohort for whom 26Gy5F would be the most appropriate.